1. Home
  2. PLSE vs RCUS Comparison

PLSE vs RCUS Comparison

Compare PLSE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLSE
  • RCUS
  • Stock Information
  • Founded
  • PLSE 2014
  • RCUS 2015
  • Country
  • PLSE United States
  • RCUS United States
  • Employees
  • PLSE N/A
  • RCUS N/A
  • Industry
  • PLSE Medical/Dental Instruments
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PLSE Health Care
  • RCUS Health Care
  • Exchange
  • PLSE Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • PLSE 1.2B
  • RCUS 1.2B
  • IPO Year
  • PLSE 2016
  • RCUS 2018
  • Fundamental
  • Price
  • PLSE $16.93
  • RCUS $19.72
  • Analyst Decision
  • PLSE Buy
  • RCUS Buy
  • Analyst Count
  • PLSE 1
  • RCUS 8
  • Target Price
  • PLSE $22.00
  • RCUS $27.63
  • AVG Volume (30 Days)
  • PLSE 138.8K
  • RCUS 1.6M
  • Earning Date
  • PLSE 11-05-2025
  • RCUS 10-28-2025
  • Dividend Yield
  • PLSE N/A
  • RCUS N/A
  • EPS Growth
  • PLSE N/A
  • RCUS N/A
  • EPS
  • PLSE N/A
  • RCUS N/A
  • Revenue
  • PLSE N/A
  • RCUS $240,000,000.00
  • Revenue This Year
  • PLSE N/A
  • RCUS N/A
  • Revenue Next Year
  • PLSE $700.00
  • RCUS N/A
  • P/E Ratio
  • PLSE N/A
  • RCUS N/A
  • Revenue Growth
  • PLSE N/A
  • RCUS N/A
  • 52 Week Low
  • PLSE $13.77
  • RCUS $6.50
  • 52 Week High
  • PLSE $25.00
  • RCUS $22.11
  • Technical
  • Relative Strength Index (RSI)
  • PLSE 43.70
  • RCUS 70.22
  • Support Level
  • PLSE $17.10
  • RCUS $16.41
  • Resistance Level
  • PLSE $18.35
  • RCUS $22.11
  • Average True Range (ATR)
  • PLSE 0.65
  • RCUS 1.33
  • MACD
  • PLSE -0.17
  • RCUS 0.21
  • Stochastic Oscillator
  • PLSE 16.16
  • RCUS 64.51

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: